美国REBOA（主动脉内球囊封堵）市场：市场规模、份额、趋势分析（按最终用途）、细分市场预测（2025-2030 年）

美国REBOA 市场的规模与趋势：

2024 年美国REBOA（主动脉内球囊封堵）市场规模价值 720 万美元，预估 2025 年至 2030 年期间复合年增长率为 23.6%。

Primetime Medical和Emergency Scientific等主要企业正在透过策略联盟、併购推动美国的REBOA设备创新。具有里程碑意义的 REBOA 导管便利套件等产品提高了手术效率，而最近获得的 FDA核准将推动市场成长。这些进步提高了可近性和有效性，扩大了 REBOA（主动脉内球囊切除术）设备的市场影响。

交通事故、跌倒、暴力等造成的创伤性损伤增加是推动美国REBOA 市场发展的关键因素。严重病例的激增增加了对 REBOA 等有效的紧急干预措施的需求。因此，这些救生设备的进步和采用不断扩大。根据美国劳工统计局（BLS）的数据，2022年美国发生了5,486起致命工作场所伤害，比2021年增加了5.7％。交通事故是第一大死因，占所有死亡人数的37.7％。 2023年，致命工作场所事故数量下降3.7％至5,283起，其中交通事故仍然是最常见的原因，占所有死亡人数的36.8％。

医疗技术的进步大大提高了 REBOA 手术的安全性和有效性。技术创新，包括改进的球囊设计、先进的导管系统和改进的成像，可以实现更精确的放置和监测。这些改进改善了患者的治疗效果，并增加了 REBOA 在创伤护理中的应用。例如，2024 年 6 月，总部位于犹他州的 Emergency Scientific 公司在获得 FDA 的 510(k) 批准后宣布首次使用其具有里程碑意义的 REBOA 导管。此导管用于暂时闭塞大血管以控制紧急出血。与传统方法相比，其先进的设计提高了咬合精度，同时减少了併发症。

医疗保健支出的增加正在推动美国REBOA 产业的扩张。对先进医疗技术和创伤护理的投资增加正在推动 REBOA 设备的采用。这种增长支持了更好的紧急干预和改善的患者治疗效果。根据美国医疗保险和医疗补助服务中心的数据，2023年美国医疗支出将达到4.9兆美元，较2022年的4.6%成长7.5%。医疗保险和私人医疗保险支出的成长速度超过2022年。 2023年，卫生部门在经济中的份额将达到17.6%，与2022年的17.4%相当，但低于2020年和2021年新冠疫情最严重时期的份额。

目录

第一章 分析方法及范围

第 2 章执行摘要

3. REBOA（主动脉内球囊钳）市场：驱动因素、趋势与范围

• 市场联动展望
  • 母市场展望
  • 相关/附随市场展望
• 市场动态
  • 市场驱动因素分析
  • 市场限制分析
• 美国REBOA（主动脉内球囊封堵）市场：分析工具
  • 产业分析：波特五力分析
  • PESTEL 分析

第 4 章。美国REBOA（主动脉内球囊封堵）市场：按最终用途进行的估计和趋势分析

• 按最终用途分類的市场占有率（2024 年和 2030 年）
• 细分仪表板
• 美国REBOA（主动脉内球囊封堵）市场：依最终用途分類的前景
• 按类型分類的市场规模预测及趋势分析（2018-2030）
  • 主动脉闭塞
  • 心臟麻痹
  • TCCC（战术性战斗伤患护理）

第五章 竞争格局

• 公司/竞争对手分类
• 供应商概况
  • 主要企业热图分析（2024年）
• 公司简介
  • Prytime Medical Devices, Inc
  • Emergency Scientific, LLC
  • Qx Medical
  • Front Line Medical Technologies

U.S. REBOA Market Size & Trends:

The U.S. resuscitative endovascular balloon occlusion of the aorta market size was valued at USD 7.2 million in 2024 and is projected to grow at a CAGR of 23.6% from 2025 to 2030. Key players such as Prytime Medical and Emergency Scientific, LLC drive REBOA device innovation in the U.S. through strategic collaborations, mergers, and acquisitions. Products like the Landmark REBOA Catheter convenience kit enhance procedural efficiency, while recent FDA approvals boost market growth. These advancements improve accessibility and effectiveness, expanding the market presence of resuscitative endovascular balloon occlusion of the aorta (REBOA) devices.

The growing number of traumatic injuries from road accidents, falls, and violence is a key factor fueling the U.S. REBOA market. This surge in critical cases increases the demand for effective emergency interventions such as REBOA. As a result, advancements and adoption of these life-saving devices continue to expand. According to the U.S. Bureau of Labor Statistics (BLS), in 2022, there were 5,486 fatal work injuries in the United States, marking a 5.7% increase from 2021. Transportation incidents were the leading cause, accounting for 37.7% of these fatalities. In 2023, the number of fatal work injuries decreased by 3.7% to 5,283, with transportation incidents remaining the most frequent cause, comprising 36.8% of fatalities.

Advancements in medical technology have greatly improved the safety and effectiveness of REBOA procedures. Innovations such as enhanced balloon designs, advanced catheter systems, and improved imaging allow for more precise placement and monitoring. These improvements lead to better patient outcomes and increased adoption of REBOA in trauma care. For instance, in June 2024, Utah-based Emergency Scientific announced the first use of its Landmark REBOA catheter after receiving FDA 510(k) clearance. The device is designed for temporary occlusion of large vessels to control emergency hemorrhages. Its advanced design improves occlusion precision while reducing complications compared to traditional methods.

Increasing healthcare spending is fueling the expansion of the U.S. REBOA industry. Higher investments in advanced medical technologies and trauma care are boosting the adoption of REBOA devices. This growth supports better emergency interventions and improved patient outcomes. According to the Centers for Medicare & Medicaid Services, in 2023, healthcare spending in the U.S. reached USD 4.9 trillion, marking a 7.5% increase, up from 4.6% in 2022. Medicare and private health insurance spending grew faster than in 2022. In 2023, the health sector accounted for 17.6% of the economy, comparable to 17.4% in 2022, but this figure is lower than the shares recorded in 2020 and 2021 at the height of the COVID-19 pandemic.

U.S. Resuscitative Endovascular Balloon Occlusion Of The Aorta Market Report Segmentation

This report forecasts revenue growth at country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2018 to 2030. For this study, Grand View Research has segmented the U.S. resuscitative endovascular balloon occlusion of the aorta market report based on end use:

• End Use Outlook (Revenue, USD Million, 2018 - 2030)
• Aortic Occlusion
• Cardiac Arrest
• Tactical Combat Casualty Care

Table of Contents

Chapter 1. Methodology and Scope

• 1.1. Market Segmentation & Scope
• 1.2. Segment Definitions
  • 1.2.1. End use
  • 1.2.2. Estimates and forecasts timeline
• 1.3. Research Methodology
• 1.4. Information Procurement
  • 1.4.1. Purchased database
  • 1.4.2. GVR's internal database
  • 1.4.3. Secondary sources
  • 1.4.4. Primary research
  • 1.4.5. Details of primary research
    • 1.4.5.1. Data for primary interviews in North America
• 1.5. Information or Data Analysis
  • 1.5.1. Data analysis models
• 1.6. Market Formulation & Validation
• 1.7. Model Details
  • 1.7.1. Volume price analysis (Model 2)
• 1.8. List of Secondary Sources
• 1.9. List of Primary Sources
• 1.10. Objectives

Chapter 2. Executive Summary

• 2.1. Market Outlook
• 2.2. Segment Outlook
  • 2.2.1. End use outlook
• 2.3. Competitive Insights

Chapter 3. U.S. Resuscitative Endovascular Balloon Occlusion of the Aorta Market Variables, Trends & Scope

• 3.1. Market Lineage Outlook
  • 3.1.1. Parent market outlook
  • 3.1.2. Related/ancillary market outlook
• 3.2. Market Dynamics
  • 3.2.1. Market driver analysis
  • 3.2.2. Market restraint analysis
• 3.3. U.S. Resuscitative Endovascular Balloon Occlusion of the Aorta Market Analysis Tools
  • 3.3.1. Industry Analysis - Porter's
    • 3.3.1.1. Supplier power
    • 3.3.1.2. Buyer power
    • 3.3.1.3. Substitution threat
    • 3.3.1.4. Threat of new entrant
    • 3.3.1.5. Competitive rivalry
  • 3.3.2. PESTEL Analysis
    • 3.3.2.1. Political landscape
    • 3.3.2.2. Technological landscape
    • 3.3.2.3. Economic landscape
    • 3.3.2.4. Social landscape
    • 3.3.2.5. Legal landscape
    • 3.3.2.6. Environmental landscape

Chapter 4. U.S. Resuscitative Endovascular Balloon Occlusion of the Aorta Market: End Use Estimates & Trend Analysis

• 4.1. End Use Market Share, 2024 & 2030
• 4.2. Segment Dashboard
• 4.3. U.S. resuscitative endovascular balloon occlusion of the aorta market By End Use Outlook
• 4.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
  • 4.4.1. Aortic Occlusion
    • 4.4.1.1. Market estimates and forecasts 2018 to 2030 (USD Million)
  • 4.4.2. Cardiac Arrest
    • 4.4.2.1. Market estimates and forecasts 2018 to 2030 (USD Million)
  • 4.4.3. Tactical Combat Casualty Care
    • 4.4.3.1. Market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 5. Competitive Landscape

• 5.1. Company/Competition Categorization
• 5.2. Vendor Landscape
  • 5.2.1. Key company heat map analysis, 2024
• 5.3. Company Profiles
  • 5.3.1. Prytime Medical Devices, Inc
    • 5.3.1.1. Company overview
    • 5.3.1.2. Financial performance
    • 5.3.1.3. Product benchmarking
    • 5.3.1.4. Strategic initiatives
  • 5.3.2. Emergency Scientific, LLC
    • 5.3.2.1. Company overview
    • 5.3.2.2. Financial performance
    • 5.3.2.3. Product benchmarking
    • 5.3.2.4. Strategic initiatives
  • 5.3.3. Qx Medical
    • 5.3.3.1. Company overview
    • 5.3.3.2. Financial performance
    • 5.3.3.3. Product benchmarking
    • 5.3.3.4. Strategic initiatives
  • 5.3.4. Front Line Medical Technologies
    • 5.3.4.1. Company overview
    • 5.3.4.2. Financial performance
    • 5.3.4.3. Product benchmarking
    • 5.3.4.4. Strategic initiatives

List of Tables

• Table 1 List of abbreviations
• Table 2 U.S. resuscitative endovascular balloon occlusion of the aorta market, by end-use, 2018 - 2030 (USD Million)

List of Figures

• Fig. 1 Market research process
• Fig. 2 Data triangulation techniques
• Fig. 3 Primary research pattern
• Fig. 4 Primary interviews in North America
• Fig. 5 Market research approaches
• Fig. 6 Value-chain-based sizing & forecasting
• Fig. 7 QFD modeling for market share assessment
• Fig. 8 Market formulation & validation
• Fig. 9 U.S. resuscitative endovascular balloon occlusion of the aorta market: Market outlook
• Fig. 10 U.S. resuscitative endovascular balloon occlusion of the aorta competitive insights
• Fig. 11 Parent market outlook
• Fig. 12 Related/ancillary market outlook
• Fig. 13 Penetration and growth prospect mapping
• Fig. 14 U.S. resuscitative endovascular balloon occlusion of the aorta market driver impact
• Fig. 15 U.S. resuscitative endovascular balloon occlusion of the aorta market restraint impact
• Fig. 16 U.S. resuscitative endovascular balloon occlusion of the aorta market strategic initiatives analysis
• Fig. 17 U.S. resuscitative endovascular balloon occlusion of the aorta market: End use movement analysis
• Fig. 18 U.S. resuscitative endovascular balloon occlusion of the aorta market: End use outlook and key takeaways
• Fig. 19 Aortic occlusion market estimates and forecast, 2018 - 2030 (USD Million)
• Fig. 20 Cardiac arrest market estimates and forecast, 2018 - 2030 (USD Million)
• Fig. 21 Tactical combat casualty care market estimates and forecast, 2018 - 2030 (USD Million)
• Fig. 22 Market share of key market players- U.S. resuscitative endovascular balloon occlusion of the aorta market